|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The tumor suppressor gene TP53 is mutated exclusively with the HYDIN, KRAS, and PTEN genes in large intestine, lung, and endometrial cancers respectively, indicating that TP53 takes part in different signaling pathways in different cancers.
|
26212640 |
2015 |
|
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
This study evaluates PTEN immunohistochemical (IHC) expression in tamoxifen-associated endometrial cancers.
|
12530022 |
2003 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
For example, PTEN/AKT pathway and its downstream targets and the mTOR (mammalian target of rapamycin) pathway have been shown to play an important role in endometrial cancer pathogenesis.
|
21495229 |
2010 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PTEN immunohistochemical loss, a common event in endometrioid-type endometrial carcinoma and associated with local immune suppression in melanoma, was not associated with PD-L1 expression or lymphocyte/macrophage infiltration of the tumor.
|
30291344 |
2019 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A tissue microarray was constructed from paraffin wax-embedded blocks from 95 endometrial carcinomas (EC), previously studied for microsatellite instability, as well as for alterations in PTEN, k-RAS and beta-catenin.
|
15481028 |
2004 |
|
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
To test the hypothesis that insulin signalling plays a key role in the development of EC in women with PCOS by measuring and comparing the expression of three key genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in endometrial tissue obtained from three groups of women; PCOS without EC, women with EC without PCOS and non-PCOS women without EC (controls).
|
26802879 |
2016 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Two series of endometrial cancer and precancer (endometrial intraepithelial neoplasia, as diagnosed by computerized morphometric analysis) tissue samples were studied, one for PTEN mutations by the use of denaturing gradient gel electrophoresis and another for PTEN protein expression by immunohistochemistry.
|
10841828 |
2000 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that in PTEN-mutated endometrial cancers, hyperactive Akt signaling downregulates progesterone receptor B (PRB) transcriptional activity, leading to overall impaired progestin responses.
|
26996671 |
2016 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia.
|
11190805 |
2001 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Multiple hamartoma syndrome (Cowden's disease).
|
4635800 |
1972 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Proliferation, transwell and apoptosis assay suggested that MDH2 enhanced the proliferation, migration and invasion but inhibited the apoptosis of endometrial cancer cell line through suppressing PTEN.
|
28189066 |
2017 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
PTEN, a tumor suppressor commonly mutated (50%) in endometrial carcinoma, is found mutated in endometrioid carcinoma of the ovary, but not in other forms of ovarian cancer.
|
11949955 |
2002 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We also studied cell blocks obtained from one PTEN-defective endometrial cancer cell line, after transfection with either a plasmid encoding wild-type PTEN or the empty vector.
|
15578076 |
2005 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Archival paraffin embedded tumour from women with endometrial cancer enrolled in NCIC CTG studies: EN5 (stage I/II) and IND 126, 148 and 160 (advanced/recurrent disease) were examined for MSI using BAT25/26 and for PTEN expression using immunohistochemistry.
|
20304627 |
2010 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
|
30569174 |
2019 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
However, not all mediators of PTEN signaling pathways have been clarified, and, during efforts to identify such molecules, we previously induced expression of the DUSP1 and BTG1 genes by introducing exogenous PTEN into endometrial cancer cell lines.
|
11310585 |
2001 |
|
Endometrial Carcinoma
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, we find that PTEN promoter methylation is relatively frequent in endometrial carcinoma.
|
11149415 |
2001 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Sprouty 2 immunohistochemical expression was assessed using 3 different tissue microarrays: one constructed from paraffin blocks of 80 samples of normal endometrium and 2 tissue microarrays containing samples of 157 endometrial carcinoma (1 tissue microarray constructed with 95 endometrial carcinomas previously studied for microsatellite instability and alterations in phosphatase and tensin homolog (PTEN), k-ras, and b-catenin, and 1 tissue microarray containing 62 endometrial carcinoma, which were also subjected to sprouty 2 promoter methylation analysis).
|
21111454 |
2011 |
|
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
miR-200a and miR-200b can promote the endometrial cancer cell growth in vitro by targeted inhibition of PTEN gene expression.
|
28647188 |
2017 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Studies in cell cultures have demonstrated that histone deacetylase inhibitors exert their antineoplastic activity by promoting expression of p21WAF1 and p27KIP1, cyclin-dependent kinase inhibitors, that have important roles in cell cycle regulation; importantly, the transcription of specific genes (e.g., E-cadherin, PTEN) that are commonly silenced in endometrial cancer is also enhanced.
|
29509243 |
2018 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Relevant to screening endometrial cancers for Lynch Syndrome, an initial PTEN immunohistochemistry determination may be able to replace the use of four mismatch repair immunohistochemical markers in 63% of patients with non-endometrioid endometrial carcinoma.
|
23599155 |
2013 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Three different human endometrial cancer cell lines known to have wild-type PTEN (HEC 1-A) or a mutated inactive PTEN protein (RL 95-2 and Ishikawa) were used for these studies.
|
15067356 |
2004 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
While most were previously reported in CRC, one mutation in PTEN was reported only in malignant endometrium cancer.
|
25617745 |
2015 |
|
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These data also suggest that location of intragenic PTEN mutations and their coexistence with the CMYC amplification may play a crucial part in the development of various subtypes of endometrial carcinoma, but this preliminary suggestion requires further research.
|
14663583 |
2004 |
|
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma.
|
25750291 |
2015 |